Peptide Comparison
MK-677 vs Hexarelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
MK-677 has stronger documented evidence (Phase 3 (not approved)) than Hexarelin (Phase 2 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| MK-677 | Hexarelin | |
|---|---|---|
| Class | Oral non-peptide ghrelin receptor agonist | GHRP; potent ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine | GHS-R1a agonist; more potent GH release than other GHRPs |
| Route | Oral | SC / Intranasal |
| Half-life | ~24 hrs | ~1 hr |
| Dosage (research) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) | 100-200 mcg SC 1-2x daily (short cycles) |
| Evidence tier | Phase 3 (not approved) | Phase 2 (not approved) |
| Research depth | 120 indexed | 158 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) | Cortisol/prolactin elevation; pituitary desensitization |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MK-677 or Hexarelin?
MK-677 has stronger documented evidence (Phase 3 (not approved)) than Hexarelin (Phase 2 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between MK-677 and Hexarelin?
MK-677 is classed as Oral non-peptide ghrelin receptor agonist; Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: MK-677, ~24 hrs; Hexarelin, ~1 hr. Routes in published studies: MK-677, Oral; Hexarelin, SC / Intranasal.
Which has stronger evidence, MK-677 or Hexarelin?
MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.
Which is more accessible, MK-677 or Hexarelin?
Neither MK-677 nor Hexarelin is an FDA-approved drug. Catalog status: MK-677, Research Chemical; Hexarelin, Research Chemical. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).
Are MK-677 and Hexarelin ever combined?
MK-677 and Hexarelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…